CCDC32

Across TCGA pan-cancer cohorts, CCDC32 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CCDC32 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CCDC32 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CCDC32 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where CCDC32 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.506	0.265	<.001	32	view →
HNSC	DFS	Tertile	All	0.907	1.000	.003	17	view →
LSCC	OS	Median	III,IV	1.000	0.750	.011	13	view →
CCRCC	DFS	Median	II,III,IV	0.827	0.359	.023	4	view →
LUAD	OS	Tertile	II,III,IV	0.734	0.434	.024	3	view →
GBM	OS	Quartile	All	0.606	0.296	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CCDC32–PDAC (DFS)

Open the PDAC breakdown →